BR112017008076A2 - controlled calcium ion level composition and solution and related process and use for reperfusion - Google Patents

controlled calcium ion level composition and solution and related process and use for reperfusion

Info

Publication number
BR112017008076A2
BR112017008076A2 BR112017008076A BR112017008076A BR112017008076A2 BR 112017008076 A2 BR112017008076 A2 BR 112017008076A2 BR 112017008076 A BR112017008076 A BR 112017008076A BR 112017008076 A BR112017008076 A BR 112017008076A BR 112017008076 A2 BR112017008076 A2 BR 112017008076A2
Authority
BR
Brazil
Prior art keywords
solution
reperfusion
calcium ion
calcium
related process
Prior art date
Application number
BR112017008076A
Other languages
Portuguese (pt)
Other versions
BR112017008076B1 (en
Inventor
White Christopher
Freed Darren
Hryshko Larry
Original Assignee
Freed Darren
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CA2015/050297 external-priority patent/WO2015154193A1/en
Application filed by Freed Darren filed Critical Freed Darren
Publication of BR112017008076A2 publication Critical patent/BR112017008076A2/en
Publication of BR112017008076B1 publication Critical patent/BR112017008076B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Chemistry (AREA)
  • Dentistry (AREA)
  • Physiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Biophysics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a presente invenção refere-se a uma solução compreende uma mistura de preservação que compreende uma fonte de íon cálcio; e um tampão para a manutenção de um ph da solução. a concentração molar de íon cálcio (ca2+) na solução é de 0,18 até 0,26 mmol/l e o ph é menor que 7,4 e maior que 6,6. uma composição para a preparação da solução pode compreender adenosina, lidocaína e uma fonte de cálcio, em que a proporção molar de adenosina:cálcio é de 0,3:0,26 até 0,45:0,18 e a proporção molar de lidocaína:cálcio é de 0,04:0,26 até 0,09:0,18. um coração do doador pode ser submetido à reperfusão com a solução. a solução pode ser utilizada para a reperfusão de um coração do doador, tal como a uma temperatura de aproximadamente 25 até aproximadamente 37°c. o doador pode ser um doador após a morte circulatória.The present invention relates to a solution comprising a preservation mixture comprising a calcium ion source; and a buffer for maintaining a ph of solution. the molar calcium ion concentration (ca2 +) in the solution is from 0.18 to 0.26 mmol / l and the ph is less than 7.4 and greater than 6.6. A composition for the preparation of the solution may comprise adenosine, lidocaine and a calcium source, wherein the molar ratio of adenosine: calcium is 0.3: 0.26 to 0.45: 0.18 and the molar ratio of lidocaine. : calcium is from 0.04: 0.26 to 0.09: 0.18. a donor heart can be reperfused with the solution. The solution may be used for reperfusion of a donor heart, such as at a temperature of about 25 to about 37 ° C. The donor may be a donor after circulatory death.

BR112017008076-1A 2014-10-24 2015-10-23 SOLUTION WITH CONTROLLED CALCIUM ION LEVEL, COMPOSITION FOR SOLUTION PREPARATION AND RELATED PROCESS AND USE FOR REPERFUSION BR112017008076B1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462068524P 2014-10-24 2014-10-24
US62/068,524 2014-10-24
PCT/CA2015/050297 WO2015154193A1 (en) 2014-04-10 2015-04-10 Modulation of calcium ion homeostasis in harvested transplantable hearts
CAPCT/CA2015/050297 2015-04-10
PCT/CA2015/051084 WO2016061700A1 (en) 2014-10-24 2015-10-23 Novel composition and solution with controlled calcium ion level, and related method and use for reperfusion

Publications (2)

Publication Number Publication Date
BR112017008076A2 true BR112017008076A2 (en) 2017-12-26
BR112017008076B1 BR112017008076B1 (en) 2021-06-29

Family

ID=55760003

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017008076-1A BR112017008076B1 (en) 2014-10-24 2015-10-23 SOLUTION WITH CONTROLLED CALCIUM ION LEVEL, COMPOSITION FOR SOLUTION PREPARATION AND RELATED PROCESS AND USE FOR REPERFUSION

Country Status (6)

Country Link
EP (1) EP3209128A4 (en)
CN (2) CN113841687A (en)
AU (1) AU2015336862B2 (en)
BR (1) BR112017008076B1 (en)
CA (1) CA2965400C (en)
WO (1) WO2016061700A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201600120839A1 (en) * 2016-12-01 2018-06-01 Valentina Valenti Cardioplegic solution with autophagy activators for the diastolic arrest of the heart during cardiac surgery
CN113303325A (en) * 2021-05-27 2021-08-27 南方医科大学南方医院 Perfusate and normal-temperature blood mechanical perfusion system suitable for rat donor heart

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5407793A (en) * 1991-10-18 1995-04-18 University Of Pittsburgh Of The Commonwealth System Of Higher Education An aqueous heart preservation and cardioplegia solution
FR2785501B1 (en) * 1998-11-10 2001-01-05 Centre Nat Rech Scient PERFUSION AND / OR PRESERVATION AND / OR REPERFUSION SOLUTION DURING ORGAN TRANSPLANTATION
EP1207753A4 (en) * 1999-06-17 2005-11-30 Univ California Continuous cardiac perfusion preservation with peg-hb for improved hypothermic storage
US20030124503A1 (en) * 2001-12-28 2003-07-03 Olivencia-Yurvati Albert H. Pyruvate cardioplegia solutions for administration to the heart during cardiopulmonary surgery and methods of use thereof
AUPS312602A0 (en) * 2002-06-21 2002-07-18 James Cook University Organ arrest, protection, preservation and recovery
FR2975869B1 (en) * 2011-05-31 2017-03-03 Hemarina ORGAN PRESERVATION COMPOSITION AND USES
ES2834388T3 (en) * 2014-04-10 2021-06-17 Tevosol Inc Modulation of calcium ion homeostasis in harvested transplantable hearts
CN103893205B (en) * 2014-04-15 2016-03-09 青岛大学附属医院 A kind ofly comprise cardioplegic solution of lignocaine and adenosine and preparation method thereof

Also Published As

Publication number Publication date
CN107105640B (en) 2021-10-12
EP3209128A4 (en) 2018-04-11
EP3209128A1 (en) 2017-08-30
WO2016061700A1 (en) 2016-04-28
CA2965400C (en) 2023-03-14
AU2015336862A1 (en) 2017-06-01
CN107105640A (en) 2017-08-29
BR112017008076B1 (en) 2021-06-29
CN113841687A (en) 2021-12-28
CA2965400A1 (en) 2016-04-28
AU2015336862B2 (en) 2018-08-09

Similar Documents

Publication Publication Date Title
UY36897A (en) STABLE INOCULATING COMPOSITIONS AND METHODS FOR PRODUCTION
BR112017013210A2 (en) methods for forming peroxiformic acid and uses of this
BR112015017405A2 (en) compositions including hydrophobizing and stabilizing agents and methods for preparing and using them
CL2017002082A1 (en) New specific proteins for pioverdine and pyoquelin
BR112018068734A2 (en) method for increasing the density of a well treatment brine
BR112015008327A2 (en) cleaning additive and cleaning method using the same
BR112015011244A8 (en) long-acting or directed cell reaction compstatin analogs and related compositions and methods
AR093310A1 (en) COMPOSITIONS AND METHODS TO IMPROVE GROWTH OF PLANTS
CR20180503A (en) COMPOSITIONS AND METHODS FOR PROGRAMMING THERAPEUTIC CELLS USING DIRECTED NUCLEIC ACID NANOPPORTERS
EA201692076A1 (en) NEW NITRIFICATION INHIBITORS
DOP2016000253A (en) NEW COMPOUNDS
EA201791182A1 (en) NEW DERIVATIVES OF 2'- AND / OR 5'-AMINO ACID ESTERS OF 3'-DEOXYADENOSINE PHOSPHOROAMIDATE AS ANTIKROSTIC COMPOUNDS
BR112016030983A8 (en) compositions for treating obesity, preventing weight gain, promoting weight loss, promoting slimming, or treating or preventing the development of diabetes, kit, method for preparing tyrphostin 9 and use
BR112018006810A2 (en) dosage regimens
BR112015017051A2 (en) method to produce acrylic acid
BR112017004925A2 (en) composition and method
EA201600398A1 (en) TIENOPYRIMIDINES AS MKNK1 AND MKNK2 INHIBITORS
NZ733952A (en) Acid composition based on leonardite and amino acids
BR112014025968A2 (en) composition and process for retanning and greasing of leather and prepared leather
BR112016006512A2 (en) organ, organ, solution conservation kits, and methods for preparing organ or tissue conservation solution and living tissue
DOP2016000251A (en) WNT SIGNALING ROAD INHIBITORS
CL2018000015A1 (en) Fusion molecules
BR112017008076A2 (en) controlled calcium ion level composition and solution and related process and use for reperfusion
UY37502A (en) CYCLIC DINUCLEOTIDE
BR112019005542A2 (en) compositions for small molecule therapeutic agent compounds

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/10/2015, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved

Owner name: TEVOSOL, INC. (CA)